for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Achillion Pharmaceuticals, Inc.

ACHN.OQ

Latest Trade

6.09USD

Change

0.00(0.00%)

Volume

1,396,673

Today's Range

6.07

 - 

6.21

52 Week Range

1.30

 - 

6.44

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Alexion Pharmaceuticals Says If Merger With Achillion Terminated Under Certain Circumstances, Achillion May Be Required To Pay Co Fee Equal To $20 Million

Oct 16 (Reuters) - Alexion Pharmaceuticals Inc <ALXN.O>::ALEXION PHARMACEUTICALS - IF MERGER WITH ACHILLION TERMINATED UNDER CERTAIN CIRCUMSTANCES, ACHILLION MAY BE REQUIRED TO PAY CO FEE EQUAL TO $20 MILLION.ALEXION - TO PAY ACHILLION TERMINATION FEE EQUAL TO $30 MILLION, $40 MILLION, $50 MILLION OR $60 MILLION DEPENDING ON EXTENSION OF MERGER END DATE, TERMINATION DATE.

Alexion To Acquire Achillion

Oct 16 (Reuters) - Achillion Pharmaceuticals Inc <ACHN.O>::ALEXION TO ACQUIRE ACHILLION.ACHILLION PHARMACEUTICALS INC - INITIAL ALL-CASH TRANSACTION FOR $6.30 PER SHARE.ACHILLION PHARMACEUTICALS INC - DEAL FOR $6.30 PER SHARE.ACHILLION PHARMACEUTICALS INC - TOTAL TRANSACTION OF UP TO $8.30 PER SHARE WITH POTENTIAL ADDITIONAL CONTINGENT CONSIDERATIONS.ACHILLION PHARMACEUTICALS INC - INITIAL DEAL CONSIDERATION OF APPROXIMATELY $930 MILLION.ACHILLION PHARMACEUTICALS INC - ALEXION WILL ALSO BE ACQUIRING CASH CURRENTLY ON ACHILLION'S BALANCE SHEET.ACHILLION PHARMACEUTICALS - DEAL INCLUDES POTENTIAL FOR ADDITIONAL CONSIDERATION IN FORM OF NON-TRADEABLE CONTINGENT VALUE RIGHTS.ACHILLION PHARMA - AS OF SEPT. 30, 2019, CASH CURRENTLY ON ACHILLION'S BALANCE SHEET WAS ABOUT $230 MILLION.ACHILLION PHARMA - CVRS WILL BE PAID TO ACHILLION SHAREHOLDERS IF SOME CLINICAL & REGULATORY MILESTONES ARE ACHIEVED WITHIN SPECIFIED PERIODS.

Achillion Receives Breakthrough Therapy Designation From FDA For Danicopan For Treatment Of Paroxysmal Nocturnal Hemoglobinuria

Sept 25 (Reuters) - Achillion Pharmaceuticals Inc <ACHN.O>::ACHILLION RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR DANICOPAN FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.ACHILLION PHARMACEUTICALS INC - INITIATION OF PHASE 3 PLANNED FOR EARLY 2020.ACHILLION PHARMACEUTICALS INC - DANICOPAN PHASE 2 PNH COMBINATION THERAPY TOPLINE DATA EXPECTED Q4 2019.

Achillion Reports Q2 Loss Per Share $0.14

Aug 8 (Reuters) - Achillion Pharmaceuticals Inc <ACHN.O>::ACHILLION REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.ACHILLION PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.14.ACHILLION PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2019 WAS $241.3 MILLION.ACHILLION PHARMACEUTICALS INC - EXPECTS NET-CASH SPEND FOR FULL YEAR OF 2019 TO BE APPROXIMATELY $85 MILLION.ACHILLION PHARMACEUTICALS - ACH-5228'S NEAR COMPLETE & SUSTAINED INHIBITION OF ALTERNATIVE PATHWAY & ITS TOLERABILITY SUPPORT US IND SUBMISSION Q419.

Achillion’S Ach-5228 Achieves Positive Results In Phase 1 Multiple Ascending Dose Study In Healthy Volunteers

July 22 (Reuters) - Achillion Pharmaceuticals Inc <ACHN.O>::ACHILLION’S ACH-5228 ACHIEVES POSITIVE RESULTS IN PHASE 1 MULTIPLE ASCENDING DOSE STUDY IN HEALTHY VOLUNTEERS.ACHILLION PHARMACEUTICALS INC - INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO BE SUBMITTED IN Q4 OF 2019.ACHILLION PHARMACEUTICALS INC - ACH-5228 DELIVERS NEAR COMPLETE AND SUSTAINED INHIBITION OF COMPLEMENT ALTERNATIVE PATHWAY.ACHILLION PHARMACEUTICALS INC - TWICE-DAILY ORAL ADMINISTRATION TO MOVE FORWARD IN PHASE 2 TRIALS.

Achillion Reports Positive Interim Data For Ach-4471 Phase 2 Combination Trial With Eculizumab At The New Era Of Aplastic Anemia And Pnh Meeting

May 17 (Reuters) - Achillion Pharmaceuticals Inc <ACHN.O>::ACHILLION REPORTS POSITIVE INTERIM DATA FOR ACH-4471 PHASE 2 COMBINATION TRIAL WITH ECULIZUMAB AT THE NEW ERA OF APLASTIC ANEMIA AND PNH MEETING.ACHILLION - ACH-4471 INCREASED HEMOGLOBIN AND NEARLY ELIMINATED NEED FOR TRANSFUSIONS IN PATIENTS WITH PNH BEING TREATED WITH C5 INHIBITOR, ECULIZUMAB.ACHILLION PHARMACEUTICALS INC - ACH-4471 WAS GENERALLY WELL TOLERATED WHEN ADDED TO ECULIZUMAB IN PATIENTS WITH PNH.ACHILLION PHARMACEUTICALS - LOOK FORWARD TO COMPLETING PHASE 2 TRIAL THIS SUMMER & FUTURE DISCUSSIONS WITH REGULATORY AUTHORITIES.ACHILLION PHARMACEUTICALS INC - HOPE TO INITIATE A PHASE 3 PNH COMBINATION TRIAL OF ACH-4471 WITH C5 INHIBITORS IN FIRST HALF OF 2020.

Achillion Pharmaceuticals Reports Q1 Loss Per Share Of $0.14

May 9 (Reuters) - Achillion Pharmaceuticals Inc <ACHN.O>::ACHILLION REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.ACHILLION PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.14.

Achillion Says Enrolled 23 Patients In Phase 2 Trials For C3 Glomerulopathy

April 3 (Reuters) - Achillion Pharmaceuticals Inc <ACHN.O>::ACHILLION ANNOUNCES ENROLLMENT MILESTONE IN PHASE 2 TRIALS FOR C3 GLOMERULOPATHY.ACHILLION PHARMACEUTICALS INC - TARGETING END-OF-PHASE 2 MEETING WITH FDA IN Q4 OF 2019.ACHILLION PHARMACEUTICALS INC - ENROLLED 23 PATIENTS IN ACH-4471 PHASE 2 C3G SIX AND 12-MONTH CLINICAL TRIALS.ACHILLION PHARMACEUTICALS INC - REMAIN ON TRACK TO PRESENT DATA FROM TWO PHASE 2 TRIALS TO U.S. FOOD AND DRUG ADMINISTRATION IN Q4 OF 2019.

Achillion Pharma Q4 Net Loss $16.6 Mln Vs Net Loss Of $23.2 Mln A Year Earlier

March 7 (Reuters) - Achillion Pharmaceuticals Inc <ACHN.O>::ACHILLION REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.ACHILLION PHARMACEUTICALS INC - WELL FUNDED WITH CASH AND SECURITIES OF $271 MILLION AT DECEMBER 31, 2018.ACHILLION PHARMACEUTICALS INC - ANTICIPATE SUBMITTING AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION IN US FOR ACH-5228 IN Q4 OF 2019.ACHILLION PHARMACEUTICALS INC QTRLY REPORTED A NET LOSS OF $16.6 MILLION, COMPARED TO A NET LOSS OF $23.2 MILLION IN THREE MONTHS ENDED DEC 31, 2017.

Achillion Announces First Dosing In Phase 1 Multiple Ascending Dose Study Of ACH-5228

Jan 31 (Reuters) - Achillion Pharmaceuticals Inc <ACHN.O>::ACHILLION ANNOUNCES FIRST DOSING IN PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF ACH-5228 NEXT-GENERATION ORAL FACTOR D INHIBITOR IN HEALTHY VOLUNTEERS.ACHILLION PHARMACEUTICALS INC - ACHILLION PLANNING INVESTIGATIONAL NEW DRUG (IND) SUBMISSION IN Q4 OF 2019.ACHILLION PHARMACEUTICALS INC - PLANNING INVESTIGATIONAL NEW DRUG (IND) SUBMISSION IN Q4 OF 2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up